• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Fungal Endocarditis Market Research Report- Global forecast till 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Fungal Endocarditis Market

    ID: MRFR/LS/3679-HCR
    85 Pages
    Rahul Gotadki
    September 2025

    Fungal Endocarditis Market Research Report Information: By Type of Fungus (Candida, Aspergillus), Diagnosis (Blood Test, X-Ray, Echocardiography, Electrocardiogram), Treatment (Antifungal Medication, Surgery, Combined Treatment), End User - Global Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Fungal Endocarditis Market Research Report- Global forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Fungal Endocarditis Market Summary

    As per Market Research Future Analysis, the Fungal Endocarditis Market was valued at USD 0.378 Billion in 2023 and is projected to grow to USD 0.673 Billion by 2032, with a CAGR of 5.43% from 2024 to 2032. This rare disease has a high mortality rate of around 50% and is primarily caused by Candida and Aspergillus species. The market is driven by increasing awareness of fungal infections, government support, and rising healthcare expenditures. However, challenges such as side effects of treatments and the prevalence of misbranded drugs may hinder growth. The Americas dominate the market, followed by Europe, while the Asia Pacific is the fastest-growing region due to improving healthcare technology.

    Key Market Trends & Highlights

    Key trends influencing the Fungal Endocarditis Market include rising awareness and advancements in treatment options.

    • Market Size in 2023: USD 0.378 Billion
    • Projected Market Size by 2032: USD 0.673 Billion
    • CAGR from 2024 to 2032: 5.43%
    • Incidence of hospitalization in the U.S.: 12.7 per 100,000 annually

    Market Size & Forecast

    2023 Market Size USD 0.378 Billion
    2024 Projected Market Size USD 0.45 Billion
    2032 Projected Market Size USD 0.673 Billion

    Major Players

    Key players include Pfizer, Merck & Co., Sanofi, Astellas Pharma, GlaxoSmithKline, Novartis, Enzon Pharmaceuticals, Bayer, Sigma-Aldrich, Abbott Laboratories, and Eli Lilly.

    Fungal Endocarditis Market Trends

    The rising incidence of fungal infections, coupled with an increasing awareness of fungal endocarditis, suggests a growing need for enhanced diagnostic and therapeutic strategies in the healthcare sector.

    Centers for Disease Control and Prevention (CDC)

    Fungal Endocarditis Market Drivers

    Rising Incidence of Fungal Infections

    The increasing prevalence of fungal infections globally appears to drive the Global Fungal Endocarditis Market Industry. Factors such as immunocompromised patients, including those with diabetes, HIV, and cancer, contribute to this rise. In 2024, the market is projected to reach 0.45 USD Billion, reflecting the urgent need for effective treatment options. As awareness of fungal infections grows, healthcare providers are likely to enhance diagnostic capabilities, further propelling market growth. This trend suggests a potential increase in the number of diagnosed cases, which may lead to a greater demand for antifungal therapies and interventions.

    Market Segment Insights

    Fungal Endocarditis Type Insights

    On the basis of the type of causative agent, the market is segmented into Candida species, Aspergillus species, and Histoplasma capsulatum.

    Fungal Endocarditis Diagnosis Insights

    On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram

    Fungal Endocarditis Treatment Insights

    On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.

    Fungal Endocarditis End-Users Insights

    On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.

    Regional Analysis

    The Americas dominate the fungal endocarditis market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

    Europe holds the second position in the fungal endocarditis market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.

    The Asia Pacific is the fastest growing fungal endocarditis market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

    Get more detailed insights about Fungal Endocarditis Market Research Report- Global forecast till 2032

    Request Free Sample

    Regional Insights

    Key Companies in the Fungal Endocarditis Market market include

    Industry Developments

    Future Outlook

    Fungal Endocarditis Market Future Outlook

    The Global Fungal Endocarditis Market is projected to grow at a 5.23% CAGR from 2024 to 2035, driven by rising incidence rates, advancements in diagnostics, and increasing awareness.

    New opportunities lie in:

    • Develop novel antifungal therapies targeting resistant strains.
    • Invest in advanced diagnostic tools for early detection.
    • Expand telemedicine services for remote patient monitoring and management.

    By 2035, the market is expected to demonstrate robust growth, reflecting enhanced treatment options and improved patient outcomes.

    Market Segmentation

    2023:

    • Academic Institutes and Universities
    • Government Research Institute
    • Diagnostic Laboratories
    • Research and Development (R&D) Companies
    • Pharmaceutical Companies

    April 2024:

    • Academic Institutes and Universities
    • Government Research Institute
    • Diagnostic Laboratories
    • Research and Development (R&D) Companies
    • Pharmaceutical Companies

    Key Players

    • Others. 
    • Eli Lily and Company, and 
    • Abbott Laboratories, 
    • Sigma-Aldrich, 
    • Bayer AG, 
    • Enzon Pharmaceuticals, Inc., 
    • Novartis AG, 
    • GlaxoSmithKline plc , 
    • Astellas Pharma, Inc., 
    • Sanofi, 
    • Merck & Co., 
    • Pfizer , 

    Intended Audience

    • Academic Institutes and Universities
    • Government Research Institute
    • Diagnostic Laboratories
    • Research and Development (R&D) Companies
    • Pharmaceutical Companies

    Regional Analysis

    • Others. 
    • Eli Lily and Company, and 
    • Abbott Laboratories, 
    • Sigma-Aldrich, 
    • Bayer AG, 
    • Enzon Pharmaceuticals, Inc., 
    • Novartis AG, 
    • GlaxoSmithKline plc , 
    • Astellas Pharma, Inc., 
    • Sanofi, 
    • Merck & Co., 
    • Pfizer , 

    Fungal Endocarditis Market Overview

    • Academic Institutes and Universities
    • Government Research Institute
    • Diagnostic Laboratories
    • Research and Development (R&D) Companies
    • Pharmaceutical Companies

    Fungal Endocarditis End-Users Insights

    • Others. 
    • Eli Lily and Company, and 
    • Abbott Laboratories, 
    • Sigma-Aldrich, 
    • Bayer AG, 
    • Enzon Pharmaceuticals, Inc., 
    • Novartis AG, 
    • GlaxoSmithKline plc , 
    • Astellas Pharma, Inc., 
    • Sanofi, 
    • Merck & Co., 
    • Pfizer , 

    Report Scope

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    What is the growth rate of the global fungal endocarditis market?

    The global fungal endocarditis market can expand at 5.43% CAGR from 2024 to 2032.

    Name the major driver of the global fungal endocarditis market?

    Massive number of cases of Candida fungal endocarditis is the major driver of the global fungal endocarditis market.

    Which region can dominate in the global fungal endocarditis market?

    The Americas can dominate the global fungal endocarditis market due to increasing awareness among the populace.

    Which is the second largest region in global fungal endocarditis market?

    Europe is the second largest region in the global fungal endocarditis market.

    Name the biggest players of the global fungal endocarditis market?

    Sanofi, Enzon Pharmaceuticals, Inc., Merck & Co., Sigma-Aldrich, Eli Lily and Company, Pfizer, GlaxoSmithKline plc, Abbott Laboratories, Bayer AG, Astellas Pharma, Inc., and Novartis AG are notable players of the global fungal endocarditis market.

    1. 'Table of Contents:
    2. Chapter 1. Report
    3. Prologue
    4. Chapter
    5. Market Introduction
    6. Definition
    7. Scope of the Study
    8. Research Objective
    9. Assumptions
    10. Limitations
    11. Chapter
    12. Research Methodology
      1. Introduction
      2. Primary Research
      3. Secondary research
      4. Market Size Estimation
    13. Chapter 4. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Challenges
      5. Macroeconomic Indicators
      6. Technology Trends & Assessment
    14. Chapter 5. Market Factor Analysis
    15. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
        1. Bargaining Power of Buyers
        2. Threat of New Entrants
        3. Threat of Substitutes
        4. Intensity of Rivalry
      2. Value Chain Analysis
      3. Investment Feasibility
    16. Analysis
    17. Pricing Analysis
    18. Chapter
    19. Global Fungal Endocarditis Market, by Type of Causative Agent
      1. Introduction
      2. Candida species
        1. Market Estimates
    20. & Forecast, 2022-2030
      1. Aspergillus species
        1. Market Estimates & Forecast, 2022-2030
      2. Histoplasma capsulatum
        1. Market Estimates
    21. & Forecast, 2022-2030
    22. Chapter 7. Global Fungal Endocarditis Market, by Diagnosis
      1. Introduction
      2. Physical Examination
        1. Market Estimates
    23. & Forecast, 2022-2030
      1. Blood Test
        1. Market Estimates & Forecast, 2022-2030
      2. X-ray
        1. Market Estimates & Forecast, 2022-2030
      3. Echocardiography
        1. Market Estimates
    24. & Forecast, 2022-2030
      1. Electrocardiogram
        1. Market Estimates & Forecast, 2022-2030
    25. Chapter 8. Global Fungal
    26. Endocarditis Market, by treatment
      1. Introduction
      2. Antifungal Medication
        1. Market Estimates & Forecast, 2022-2030
      3. Surgery
        1. Market Estimates
    27. & Forecast, 2022-2030
      1. Combined Treatment
        1. Market Estimates & Forecast, 2022-2030
    28. Chapter 9. Global Fungal
    29. Endocarditis Market, by End User
      1. Introduction
      2. Hospital
        1. Market Estimates & Forecast, 2022-2030
      3. Clinics
        1. Market Estimates &
    30. Forecast, 2022-2030
    31. Diagnostic Centers
    32. Market Estimates & Forecast, 2022-2030
      1. Others
        1. Market Estimates & Forecast, 2022-2030
    33. Chapter 10. Global Fungal
    34. Endocarditis Market, by Region
      1. Introduction
      2. Americas
        1. North America
        2. South America
      3. Europe
        1. Western Europe
        2. Eastern Europe
      4. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. Republic of Korea
        6. Rest of Asia Pacific
      5. The Middle East & Africa
        1. United Arab Emirates
        2. Saudi Arabia
        3. Oman
        4. Kuwait
        5. Qatar
        6. Rest of the Middle
    35. East & Africa
    36. Chapter
    37. Company Landscape
    38. Introduction
    39. Market Share Analysis
    40. Key Development & Strategies
      1. Key Developments
    41. Chapter 12 Company Profiles
      1. Pfizer
        1. Company Overview
        2. Type of Causative Agents Overview
        3. Financials
        4. SWOT Analysis
      2. Merck & Co.
        1. Company Overview
        2. Type of Causative
    42. Agents Overview
    43. Financial Overview
    44. Key Developments
    45. SWOT Analysis
    46. Sanofi
    47. Company Overview
    48. Type of Causative Agents Overview
      1. Financial Overview
        1. Key Development
        2. SWOT Analysis
      2. Astellas Pharma, Inc.
        1. Company Overview
        2. Type of Causative Agents/Business Segment
    49. Overview
    50. Financial Overview
    51. Key Development
    52. SWOT Analysis
    53. GlaxoSmithKline plc
    54. Company Overview
    55. Type of Causative Agents Overview
      1. Financial overview
        1. Key Developments
      2. Novartis AG
        1. Company Overview
        2. Type of Causative Agents Overview
        3. Financial Overview
        4. Key Developments
      3. ENZON PHARMACEUTICALS
        1. Overview
        2. Type of Causative
    56. Agents Overview
    57. Financials
    58. Key Developments
    59. SWOT Analysis
    60. Others
    61. Chapter
    62. MRFR Conclusion
    63. Key Findings
    64. From CEO’s View Point
      1. Unmet Needs of the Market
      2. Key Companies to Watch
      3. Prediction of Fungal Endocarditis industry
    65. Chapter 14 Appendix
    66. Endocarditis Industry Synopsis, 2022-2030
    67. Forecast, 2022-2030, (USD Million)
    68. (USD Million)
    69. Fungal Endocarditis Market by Type of Causative Agent, 2022-2030, (USD Million)
    70. Market by Diagnosis, 2022-2030, (USD Million)
    71. 2030, (USD Million)
    72. Fungal Endocarditis Market by Type of Causative Agent, 2022-2030, (USD Million)
    73. Fungal Endocarditis Market by Diagnosis, 2022-2030, (USD Million)
    74. Endocarditis Market by Treatment, 2022-2030, (USD Million)
    75. by End Users, 2022-2030, (USD Million)
    76. Agent, 2022-2030, (USD Million)
    77. Million)
    78. US Fungal Endocarditis Market by Treatment, 2022-2030, (USD Million)
    79. Market by End Users, 2022-2030, (USD Million)
    80. of Causative Agent, 2022-2030, (USD Million)
    81. 2030, (USD Million)
    82. (USD Million)
    83. Canada Fungal Endocarditis market by End Users, 2022-2030, (USD Million)
    84. Fungal Endocarditis Market by Type of Causative Agent, 2022-2030, (USD Million)
    85. Fungal Endocarditis Market by Diagnosis, 2022-2030, (USD Million)
    86. Endocarditis Market by Treatment, 2022-2030, (USD Million)
    87. by End Users, 2022-2030, (USD Million)
    88. Agent, 2022-2030, (USD Million)
    89. (USD Million)
    90. Europe Fungal Endocarditis Market by Treatment, 2022-2030, (USD Million)
    91. Endocarditis Market by End Users, 2022-2030, (USD Million)
    92. by Type of Causative Agent, 2022-2030, (USD Million)
    93. by Diagnosis, 2022-2030, (USD Million)
    94. 2030, (USD Million)
    95. (USD Million)
    96. Eastern Europe Fungal Endocarditis Market by Type of Causative Agent, 2022-2030,
    97. (USD Million)
    98. Eastern Europe Fungal Endocarditis market by Diagnosis, 2022-2030, (USD Million)
    99. Fungal Endocarditis Market by Treatment, 2022-2030, (USD Million)
    100. Endocarditis Market by End Users, 2022-2030, (USD Million)
    101. by Type of Causative Agent, 2022-2030, (USD Million)
    102. by Diagnosis, 2022-2030, (USD Million)
    103. 2030, (USD Million)
    104. (USD Million)
    105. Middle East & Africa Fungal Endocarditis Market by Type of Causative Agent,
    106. 2030, (USD Million)
    107. 2030, (USD Million)
    108. 2030, (USD Million)
    109. Users, 2022-2030, (USD Million)
    110. Market Dynamics for Fungal Endocarditis Market
    111. by Type of Causative Agent 2020
    112. Endocarditis market Share, by Treatment 2020
    113. by End Users, 2020
    114. Global Fungal Endocarditis market Share, by Region, 2020
    115. Share, by Country, 2020
    116. Fungal Endocarditis market Share, by Country, 2020
    117. market Share, by Country, 2020
    118. Pfizer: Key Financials
    119. Co.: Key Financials
    120. Merck & Co.: Segmental Revenue
    121. Financials
    122. Sanofi: Segmental Revenue
    123. Inc.: Segmental Revenue
    124. Key Financials
    125. GlaxoSmithKline plc: Segmental Revenue
    126. Key Financials
    127. Novartis AG: Segmental Revenue
    128. Segmental Revenue
    129. ENZON PHARMACEUTICALS: Geographical Revenue'

    Fungal Endocarditis Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Fungal Endocarditis Market Research Report- Global forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027